Skip to main content

Market Overview

Biogen Rallies On Positive Alzheimer's Drug Trial

Biogen Rallies On Positive Alzheimer's Drug Trial

Shares of Biogen Inc (NASDAQ: BIIB) soared higher by more than 13 percent early Friday morning in reaction to the results of an Alzheimer's disease study. 

What Happened

Biogen and its Japanese partner Eisai Co released a final analysis of 856 patients in a Phase 2 clinical study in early Alzheimer's disease on Thursday afternoon. The BAN2401 therapy demonstrated a statistically significant slowing in clinical decline and reduction of amyloid beta accumulated in the brain.

The therapy failed to meet its primary goal of demonstrating superior results over a placebo over a 12-month period. Yet the trial did show a significant slowing of disease progression on key clinical endpoints after 18 months of treatment in patients who received the highest treatment dose of 10 mg/kg biweekly versus a placebo.

Why It's Important

Dr. Lynn Kramer, Eisai's chief medical officer, said in the press release the study proved a "very important correlation" in that it showed slowing progression of the disease after 18 months as well as a reduction of amyloid accumulation. 

What's Next

Biogen and Eisai only discussed top-line results from the study, according to the website Stat. The companies will present additional data from the clinical trial at a future medical meeting.

The two companies also said they plan to disuss a large-scale study with American and European regulators with the ultimate outcome of securing approval of BAN2401, according to Stat. 

Related Links:

Barron's Picks And Pans: Apple, Mastercard, Sirius XM, Verizon And More

Biogen's Core Business Impresses While Potential Alzheimer's Catalyst Looms


Related Articles (BIIB)

View Comments and Join the Discussion!

Posted-In: Alzheimers amyloid BAN2401 EisaiBiotech News Top Stories General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at